T2 Biosystems achieves successful patent defense for method for detecting pathogens directly from whole blood in the European Union

LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis pathogens and antibiotic resistance genes, today announced that it has successfully defended its patent for a key detection method directly from whole blood in the European Union.

The opposition was filed in May 2023 at the European Patent Office (EPO) by bioMerieux and a straw person representing other undisclosed companies against T2 Biosystems’ European Patent No. 3,443,124, which relates to a method for amplifying a target nucleic acid characteristic of a pathogen in a whole blood sample. This patent is part of T2 Biosystems’ intellectual property portfolio surrounding its proprietary method for detecting pathogens directly from whole blood. The EPO’s Opposition Division held a public hearing on 19 September 2024 and ruled that T2 Biosystems’ strong intellectual property position in the field of detecting pathogens directly from whole blood was maintained.

“This decision further demonstrates the confidence we have in the broad scope of our IP portfolio protecting our proprietary method for detecting pathogens directly from whole blood,” said John Sperzel, president and CEO of T2 Biosystems. “Given the importance and value of our IP portfolio, we intend to continue to defend against such challenges and remain confident in our leadership position as we advance our technology, commercial platform and product pipeline.”

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping physicians treat patients more effectively and faster than ever before. T2 Biosystems products are powered by proprietary T2 magnetic resonance imaging (T2MR^®) technologies and include T2Dx^® T2Bacteria Tool^® Panel, T2Candida^® Panel, T2Resistance^® Panel and T2Biothreat Panel. T2 Biosystems has an active line of future products including the US T2Resistance Panel, the T2Lyme Panel and the expanded T2Candida Panel to add detection Candida auris. For more information, visit www.t2biosystems.com.

Forecast statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical statements should be considered forward-looking statements, including, without limitation, statements regarding our patent portfolio, the potential of our technology and products to detect directly from whole blood, statements regarding our patent portfolio, and statements containing the words “expect,” “may,” “should,” “anticipate” and similar statements of a forward-looking or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are not promises or guarantees but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, agreements or products; (b) successfully execute strategic priorities; (c) launch products; (d) expand product use or adoption; (e) obtain customer feedback; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure to provide early data in anticipation of ultimate results; (iii) failure to file or obtain anticipated FDA filings or approvals within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, or the SEC, on April 1, 2024, and in other documents filed by the Company with the SEC from time to time, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These and other important factors could cause actual results to differ materially from those indicated in the forward-looking statements contained in this press release. Any such forward-looking statements constitute management’s estimates as of the date of this press release. Although the Company may elect to update such forward-looking statements at some point in the future, unless required by law, the Company disclaims any obligation to do so, even if subsequent events cause its views to change. Therefore, no one should assume that the Company’s silence at the time means that actual events expressed or implied in such forward-looking statements have been confirmed. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of this press release.

Contact for investors:
Philip Trip Taylor, Gilmartin Group
[email protected]
415-937-5406